FDA Plays

[colorofmoney]

TDLP News..Transdel Pharmaceuticals Enters into License Agreement with Jan Marini Skin
Research for Cosmeceutical Product

Agreement Includes Exclusive U.S. License to Transdel's Delivery Technology for
Use in an Anti-Cellulite Cosmeceutical Product

LA JOLLA, Calif., June 17, 2010 /PRNewswire via COMTEX/ -- Transdel
Pharmaceuticals, Inc. (TDLP) ("Transdel") and Jan Marini Skin Research, Inc.
("JMSR") have entered into a licensing agreement providing JMSR with the
exclusive U.S. rights to Transdel's transdermal delivery technology for use in an
anti-cellulite cosmeceutical product for the dermatological market.

Under the terms of the agreement, JMSR will pay Transdel a licensing royalty on
the U.S. and worldwide sales of an anti-cellulite product using Trandel's
delivery technology. JMSR obtained an exclusive right to promote and sell a
product in the U.S. dermatological market for approximately one-year after which
time they have a non-exclusive right. Also, JMSR obtained a non-exclusive right
to promote and sell the product in the ex-U.S. dermatological market.

"We are very excited with the establishment of our relationship with JMSR and
look forward to building on this relationship in order to potentially launch
additional cosmeceutical products," stated John Lomoro, Acting Chief Executive
Officer and Chief Financial Officer. "They are a recognized leader in the
dermatological market, so we are confident they will fully capitalize on the
potential for this anti-cellulite technology."

"We believe that Transdel's anti-cellulite technology has the potential to
provide us with an excellent opportunity in the dermatological market not only in
the U.S. but also for the international market," stated Jan Marini, JMSR's
President and Chief Executive Officer. "We look forward to collaborating with
Transdel on this project and potentially other product opportunities."

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (TDLP) is a specialty pharmaceutical company
developing non-invasive, topically delivered products. The Company's
innovative-patented Transdel(TM) cream formulation technology is designed to
facilitate the effective penetration of a variety of products through the tough
skin barrier. Ketotransdel(R), the Company's lead pain product, has completed a
Phase 3 clinical trial and utilizes the Transdel(TM) technology to deliver the
active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin
directly into the underlying tissues where the drug exerts its well-known
anti-inflammatory and analgesic effects. The Company intends to leverage its
Transdel(TM) platform technology to expand and create a portfolio of topical
products for a variety of indications. The Company is actively pursuing
partnerships with companies to expand its product portfolio for pharmaceutical
and cosmetic/cosmeceutical products. For more information, please visit
http://www.transdelpharma.com.

About Jan Marini Skin Research, Inc.

San Jose, CA-based Jan Marini Skin Research, Inc. ("JMSR") is a recognized leader
and innovator in skin care, providing state-of-the-art technologies and
breakthroughs in medically based skin care therapies. The JMSR Skin Care
Management Center is used and trusted by physicians and skin care professionals
worldwide to ensure optimum results for their patients and clients.

Safe Harbor Statement

The Company cautions you that the statements included in this press release that
are not a description of historical facts are forward-looking statements. These
include statements regarding: the Company's interpretation of the results of its
Phase 3 clinical trial for Ketotransdel(R); the Company's ability to obtain
regulatory approval to market Ketotransdel; and the Company's ability to complete
additional development activities for products utilizing its proprietary
transdermal delivery platform. Actual results may differ materially from those
set forth in this press release due to the risks and uncertainties inherent in
the Company's business, including, without limitation: the outcome of the final
analyses of the data from the Phase 3 clinical trial may vary from the Company's
initial conclusions; the FDA may not agree with the Company's interpretation of
such results or may challenge the adequacy of the Company's clinical trial design
or the execution of the clinical trial; the FDA may continue to require the
Company to complete additional clinical trials for Ketotransdel(R) before the
Company can submit a 505(b)(2) NDA application; the results of any future
clinical trials may not be favorable and the Company may never receive regulatory
approval for Ketotransdel(R); and the Company's current need to raise additional
funding to complete its product development plans. More detailed information
about the Company and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings with the
Securities and Exchange Commission, including its Annual Report on Form 10-K and
its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read
free of charge on the SEC's web site at http://www.sec.gov. You are cautioned not
to place undue reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement and the Company undertakes no obligation to
revise or update this press release to reflect events or circumstances after the
date hereof. This caution is made under the safe harbor provisions of Section 21E
of the Private Securities Litigation Reform Act of 1995.

SOURCE Transdel Pharmaceuticals, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved